# LB4330

Source: https://onco.cc/drugs/lb4330/  
OnCo record `lb4330` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

LB4330 is an experimental fusion protein from L & L Bio, Ningbo, China in phase 2 trials, aimed at Claudin 18.2.

## Summary

LB4330 is a fusion protein developed by L & L Bio, Ningbo, China. Its target is Claudin 18.2 (the sponsor names Claudin18.2 x IL-10). The sponsor states: Anti-Claudin18.2/IL-10 fusion protein combining tumour-antigen targeting with an immunomodulatory cytokine, given in combination with LB1410. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial. The largest, NCT06468358, plans to enrol 194 participants with primary completion expected 2026-12-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: fusion protein
- Mechanism: Anti-Claudin18.2/IL-10 fusion protein combining tumour-antigen targeting with an immunomodulatory cytokine, given in combination with LB1410.

## Sources

- ClinicalTrials.gov: trials of LB4330: https://clinicaltrials.gov/search?intr=LB4330

## Connected records

- targets: [Claudin 18.2](https://onco.cc/targets/cldn18-2/), [Interleukin-10 (IL10)](https://onco.cc/targets/il10/)
- companies: [Hutchmed](https://onco.cc/companies/hutchmed/)
- trials: [A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct06468358/)

---
JSON: https://onco.cc/api/v1/entities/lb4330.json